Janardanan Subramonia Kumar

Dr. Janardanan Subramonia Kumar

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
MAMatcha Angelin
Matcha Angelin
JKJanardanan Subramonia Kumar
Janardanan Subramonia Kumar
LVLeela Kakithakara Vajravelu
Leela Kakithakara Vajravelu
ASAbhishek Satheesan
Abhishek Satheesan
VCVenkata Chaithanya
Venkata Chaithanya
\A\R\Nmatcha Angelin
\R\Nmatcha Angelin
Diabetes is a significant global health concern, highlighting the critical role of dietary strategies in its management and prevention. Artificial sweeteners (ASs), due to their capacity to provide sweetness without contributing to caloric intake, have emerged as a potential tool in diabetes management. This review thoroughly examines the nuanced relationship between artificial sweeteners and diabetes, addressing their benefits and potential risks. ASs have been shown to aid in weight management, a key factor in reducing diabetes risk, and do not impact immediate blood glucose levels, offering improved glucose control for individuals with diabetes. Beyond these benefits, however, artificial sweeteners may interact complexly with gut microbiota, potentially altering its composition and affecting metabolic health. This interaction introduces concerns regarding insulin sensitivity and the risk of insulin resistance, with studies reporting conflicting findings. This comprehensive review highlights the importance of a nuanced approach to understanding the implications of artificial sweeteners in diabetes management. Given the mixed evidence on their health effects, there is a clear need for further research to fully elucidate the role of artificial sweeteners in metabolic health and their suitability as part of dietary interventions for diabetes.

19 August 2024 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
ASAbhishek Satheesan
Abhishek Satheesan
JKJanardanan Subramonia Kumar
Janardanan Subramonia Kumar
KLKakithakara Vajravelu Leela
Kakithakara Vajravelu Leela
RMRia Murugesan
Ria Murugesan
VCVenkata Chaithanya
Venkata Chaithanya
MAMatcha Angelin
Matcha Angelin

7 February 2025 in Physiology & Behavior
Verified
Journal Article
Closed access
RMRia Murugesan
Ria Murugesan
JKJanardanan Subramonia Kumar
Janardanan Subramonia Kumar
KLKakithakara Vajravelu Leela
Kakithakara Vajravelu Leela
SMSachdev Meenakshi
Sachdev Meenakshi
ASAppandraj Srivijayan
Appandraj Srivijayan
VCVenkata Chaithanya
Venkata Chaithanya

9 August 2023 in Diabetes Epidemiology and Management
Verified
Journal Article
Open access
VCVenkata Chaithanya
Venkata Chaithanya
JKJanardanan Subramonia Kumar
Janardanan Subramonia Kumar
KLKakithakara Vajravelu Leela
Kakithakara Vajravelu Leela
RMRia Murugesan
Ria Murugesan
MAMatcha Angelin
Matcha Angelin
ASAbhishek Satheesan
Abhishek Satheesan

11 August 2025 in Journal of Physiology and Biochemistry
Verified
Journal Article
Closed access
ASAbhishek Satheesan
Abhishek Satheesan
JKJanardanan Subramonia Kumar
Janardanan Subramonia Kumar
KLKakithakara Vajravelu Leela
Kakithakara Vajravelu Leela
RLRahul Harikumar Lathakumari
Rahul Harikumar Lathakumari
MAMatcha Angelin
Matcha Angelin
VCVenkata Chaithanya
Venkata Chaithanya

14 November 2024 in Life
Verified
Journal Article
Open access
PDF file
VCVenkata Chaithanya
Venkata Chaithanya
JKJanardanan Subramonia Kumar
Janardanan Subramonia Kumar
KLKakithakara Vajravelu Leela
Kakithakara Vajravelu Leela
MMMohanram M
Mohanram M
JTJayaprakash Thulukanam
Jayaprakash Thulukanam
Hyperglycemia, a key characteristic of type 2 diabetes mellitus (T2DM), highlights the need for effective management strategies. This study aims to analyze the impact of multistrain probiotic supplementation on glycemic control in T2DM patients. During a 24-week randomized controlled trial involving 130 participants, subjects were assigned to either a probiotic group or a placebo group. The key outcomes included fasting blood glucose (FBG), postprandial blood glucose (PPBG), glycated hemoglobin (HbA1c) levels, and lipid profiles, assessed at baseline and post-intervention. The results indicated a significant reduction in HbA1c (p = 0.004) and increased HDL-c (p = 0.023) and improvements in lipid profiles in the probiotic group, alongside a trend toward decreased FBG and PPBG. No serious adverse effects were reported, indicating good tolerance of probiotics. These findings suggest that probiotics may positively influence metabolic parameters in T2DM patients, supporting their potential as a complementary dietary intervention. Further research is needed to understand the underlying mechanisms and enhance probiotic formulations for diabetic control.